Immunotherapy on the Horizon in Gastric Cancer
While the utilization of immunotherapy in gastric cancer may not be as clear cut as it is in melanoma or lung cancer,... Read More
Proper Classification, Multidisciplinary Approach Key in Gastric Cancer
Not all gastroesophageal junction (GEJ) cancers should be treated the same, according to Richard J. Bold, MD, chief, Surgical Oncology, professor, UC... Read More
Apatinib Shows Promising Survival Advantage in Advanced Gastric Cancer
Apatinib demonstrated an improvement in overall survival (OS) by 1.8 months and an acceptable toxicity profile compared to placebo as treatment for... Read More
Health IT Essential for the Success of Cancer Moonshot
Gregory C. Simon, executive director, White House Cancer Task Force, spoke at the National Comprehensive Cancer Network Policy Summit in Washington, DC.... Read More
A Novel, Targeted Drug Yields Promising Results in Stomach and Esophageal Cancer at ASCO
An antibody that binds a protein present in a subset of gastric tumors has been shown to extend survival in patients with... Read More
Understanding the Underlying Mechanisms of Gastric and Esophageal Cancer
Understanding how gastric and esophageal cancers are triggered and their genetic makeup is vital to developing and testing new therapies, according to... Read More
Immunotherapy Continues to Show Promise in Treating Gastric Cancers
In the phase 1b JAVELIN trial, pretreated patients with gastric/gastroesophageal junction cancers (GC/GEJ) responded well to avelumab, a PD-L1 antibody.
Survey Seeks Gastric Patients with ROS1 Gene Fusions
A respected cancer foundation is collaborating with Stanford University to focus on a subset of cancer patients whose tumors have ROS1 gene... Read More
Landmark cancer study reveals huge regional gaps in incidence rates; lifestyle habits may be to blame
A landmark study of cancer diagnoses in Japan has revealed huge regional gaps in incidence rates in what one official said reflected... Read More
FDA Grants Napabucasin Orphan Drug Status for Gastric Cancer
Boston Biomedical announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for its investigational compound, napabucasin, for the... Read More